Fig. 3. OTUD6A oligonucleotides markedly suppress prostate tumorigenesis derived from Pten^PC−/− mice and patient-derived xenograft (PDX) models.

a, b Established Pten^PC−/− male mice were injected with AAV-GFP or AAV-shOTUD6A into VP tissues at 2-month-age. Three months later, VP part of prostates were imaged (a) and weighted (b) (n = 5–6). The Pten^fl/fl mice were used as the negative control. Data represented the mean ± SEM. c H&E-stained sections of representative VP tissues, scale bars: 100 μm. d IB analysis of PTEN and OTUD6A in different mouse prostates. e–g The PCa PDX model was constructed and the PDX tumor tissues were subcutaneously injected into the flank of 6-week-old NOD/SCID mice, and then AAV-GFP or AAV-shOTUD6A were intratumorally administrated. The growth curves were shown in (e), and the mean tumor growth inhibition rate (TGI) of each monitoring point was shown in (f). The dissected tumors were collected and weighed (g) around 4 weeks later (n = 6). Data represented the mean ± SEM. Statistical significance was determined by two-tailed unpaired Student’s t-test, *P < 0.05, **P < 0.01, ***P < 0.001. h Equal amounts of proteins from tumor tissues were evaluated for OTUD6A.